Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols.

abstract：:Acute immune thrombocytopenic purpura (ITP) occurs most commonly in young children who present with severe isolated thrombocytopenia and purpura. A marrow examination is not required unless glucocorticoids are used, lest treatment mask incipient acute lymphoblastic leukemia, but controversy exists here. The recommenda...

journal_title：Pediatric blood & cancer

authors： Segel GB,Feig SA

更新日期：2009-09-01 00:00:00

abstract：:Obesity is increasing in prevalence in the United States with over 65% of adults considered overweight and 16% of children with BMI > 95 percentile. The heritability of obesity is estimated between 40% and 70%, but the genetics of obesity for most individuals are complex and involve the interaction of multiple genes a...

journal_title：Pediatric blood & cancer

authors： Chung WK

更新日期：2012-01-01 00:00:00

abstract：:We report three cases of hemophagocytic lymphohistiocytosis (HLH) in infants within the first 6 weeks of life. Diagnosis of HLH was made early after symptoms started. All three cases were successfully treated with dexamethasone and none relapsed, indicating that not all cases of HLH in very young infants are familial....

journal_title：Pediatric blood & cancer

authors： Tanoshima R,Takahashi H,Hokosaki T,Yamaguchi K,Goto S,Kai S

更新日期：2009-01-01 00:00:00

abstract：:Twenty-eight patients were maintained on subcutaneous immunoglobulin replacement for persistent B-cell aplasia and agammaglobulinemia following CD19-targeted chimeric antigen receptor T-cell therapy for B-cell lymphoblastic leukemia. Patients were transitioned from intravenous to subcutaneous immunoglobulin replacemen...

journal_title：Pediatric blood & cancer

authors： Arnold DE,Maude SL,Callahan CA,DiNofia AM,Grupp SA,Heimall JR

更新日期：2020-03-01 00:00:00

abstract：PURPOSE:We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic properties of vorinostat, a histone deacetylase (HDAC) inhibitor, when given in combination with temozolomide in children with refractory or recurrent CNS malignancies. PATIE...

journal_title：Pediatric blood & cancer

authors： Hummel TR,Wagner L,Ahern C,Fouladi M,Reid JM,McGovern RM,Ames MM,Gilbertson RJ,Horton T,Ingle AM,Weigel B,Blaney SM

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Specialized pediatric cancer centers (PCCs) are thought to be essential to obtain state-of-the-art care for children and adolescents. We determined the proportion of childhood cancer patients not treated in a PCC, and described their characteristics and place of treatment. PROCEDURE:The Swiss Childhood Canc...

journal_title：Pediatric blood & cancer

authors： Adam M,von der Weid N,Michel G,Zwahlen M,Lutz JM,Probst-Hensch N,Niggli F,Kuehni C,Swiss Pediatric Oncology Group (SPOG).,Swiss Association of Cancer Registries (ASRT).

更新日期：2010-05-01 00:00:00

abstract：:Optic pathway gliomas (OPG) in neurofibromatosis type 1 (NF1) usually remain localized to the anterior visual pathway. However, a small number can demonstrate widespread dissemination. We describe three children with NF1 OPGs and extensive central nervous system involvement. In one case, a postmortem examination revea...

journal_title：Pediatric blood & cancer

authors： Shaikh F,Johnston D,Michaud J,Hurteau J,Vassilyadi M,Keene D

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Fanconi anemia (FA) predisposes to hematologic disorders and myeloid neoplasia in childhood and to solid cancers, mainly oral carcinomas, in early adulthood. Few cases of solid cancers have been reported in childhood. PROCEDURES:We conducted a national retrospective study of solid tumors occurring in patien...

journal_title：Pediatric blood & cancer

authors： Malric A,Defachelles AS,Leblanc T,Lescoeur B,Lacour B,Peuchmaur M,Maurage CA,Pierron G,Guillemot D,d'Enghien CD,Soulier J,Stoppa-Lyonnet D,Bourdeaut F

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:Neurocognitive impairment occurs in 20-40% of childhood acute lymphoblastic leukemia (ALL) survivors, possibly mediated by folate depletion and homocysteine elevation following methotrexate treatment. We evaluated the relationship between folate pathway polymorphisms and neurocognitive impairment after child...

journal_title：Pediatric blood & cancer

authors： Kamdar KY,Krull KR,El-Zein RA,Brouwers P,Potter BS,Harris LL,Holm S,Dreyer Z,Scaglia F,Etzel CJ,Bondy M,Okcu MF

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:The objectives of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies. PROCEDURE:Twenty-three patients between 1 and 21 years of age, with a solid...

journal_title：Pediatric blood & cancer

authors： Bomgaars L,Kerr J,Berg S,Kuttesch J,Klenke R,Blaney SM

更新日期：2006-01-01 00:00:00

abstract：:We evaluated the in vitro glucocorticoid (GC) responsiveness of 117 pediatric acute myeloid leukemia cells by considering GC resistance, GC-induced proliferation, and GC-induced differentiation. None of the samples was highly GC sensitive, and only 15% were intermediately sensitive. GC-induced differentiation was not ...

journal_title：Pediatric blood & cancer

authors： Klein K,Haarman EG,de Haas V,Zwaan ChM,Creutzig U,Kaspers GL

更新日期：2016-08-01 00:00:00

abstract：BACKGROUND:Juvenile xanthogranuloma (JXG) is the most common non-Langerhans cell histiocytosis in children. The mortality and morbidity of JXG with extracutaneous lesions remain unclear. METHODS:Data of patients aged < 18 years who were diagnosed with JXG between 2001 and 2010 were retrospectively collected through a ...

journal_title：Pediatric blood & cancer

authors： Maeda M,Morimoto A,Shioda Y,Asano T,Koga Y,Nakazawa Y,Kanegane H,Kudo K,Ohga S,Ishii E,Histiocytosis Study Group of the Japanese Society of Pediatric Hematology\/Oncology.

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:The potential role of VEGF in osteosarcoma has been evaluated in several studies. The majority of them included heterogeneous and limited series of patients, giving conflicting results. The aim of presented study is to evaluate the prognostic role of VEGF-A in biopsy samples of clinically homogeneous group o...

journal_title：Pediatric blood & cancer

authors： Ługowska I,Woźniak W,Klepacka T,Michalak E,Szamotulska K

更新日期：2011-07-15 00:00:00

abstract：:Juvenile myelomonocytic leukemia (JMML) has a poor prognosis in general, with hematopoietic stem cell transplant (HSCT) remaining the standard of care for cure. The hypomethylating agent, azacitidine, has been used as a bridging therapy to transplant. However, no patients have been treated with azacitidine without an ...

journal_title：Pediatric blood & cancer

authors： Hashmi SK,Punia JN,Marcogliese AN,Gaikwad AS,Fisher KE,Roy A,Rao P,Lopez-Terrada DH,Ringrose J,Loh ML,Niemeyer CM,Rau RE

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveilla...

journal_title：Pediatric blood & cancer

authors： Malogolowkin M,Spreafico F,Dome JS,van Tinteren H,Pritchard-Jones K,van den Heuvel-Eibrink MM,Bergeron C,de Kraker J,Graf N,COG Renal Tumors Committee and the SIOP Renal Tumor Study Group.

更新日期：2013-10-01 00:00:00

abstract：:Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of ...

journal_title：Pediatric blood & cancer

authors： Rodriguez V,Anderson PM,Trotz BA,Arndt CA,Allen JA,Khan SP

更新日期：2007-08-01 00:00:00

abstract：OBJECTIVE:To develop an objective tool for assessing disease activity in patients with Langerhans cell histiocytosis (LCH). METHOD:Scoring system was developed and applied to a database containing information on 612 patients. RESULTS:At diagnosis, the score distribution was highly asymmetrical: the score was between ...

journal_title：Pediatric blood & cancer

authors： Donadieu J,Piguet C,Bernard F,Barkaoui M,Ouache M,Bertrand Y,Ibrahim H,Emile JF,Hermine O,Tazi A,Genereau T,Thomas C

更新日期：2004-12-01 00:00:00

abstract：:The Standards, Options, and Recommendations (SOR) project undertaken by the French National Federation of Cancer Centers (FNCLCC) to develop and disseminate clinical practice guidelines in oncology has now been taken over by the French National Cancer Institute. In 2007, the SOR updated the information related to the ...

journal_title：Pediatric blood & cancer

authors： Marec-Berard P,Chastagner P,Kassab-Chahmi D,Casadevall N,Marchal C,Misset JL,Ray-Coquard I

更新日期：2009-07-01 00:00:00

abstract：:Granulocytic sarcoma (GS) is a localized tumor composed of immature myeloid cells. This extramedullary tumor can present before, concurrent with or after the diagnosis of acute myeloid leukemia. GS is extremely uncommon in acute promyelocytic leukemia (APL). As a proportion of patients never develop systemic disease, ...

journal_title：Pediatric blood & cancer

authors： Worch J,Ritter J,Frühwald MC

更新日期：2008-03-01 00:00:00

abstract：:With improvements in therapy for childhood cancer, the expectation that most childhood cancer patients will survive and enter adulthood is a reality. There is clear evidence that survivors are at risk for adverse health-related long-term sequelae associated with their cancer and its treatment, requiring appropriate he...

journal_title：Pediatric blood & cancer

authors： Friedman DL,Freyer DR,Levitt GA

更新日期：2006-02-01 00:00:00

abstract：BACKGROUND:Few studies have addressed the efficacy of palliative radiotherapy (RT) for pediatric osteosarcoma (OS), a disease generally considered to be radioresistant. We describe symptom relief, local control, and toxicity associated with palliative RT among children with OS. PROCEDURE:Patients diagnosed with OS at ...

journal_title：Pediatric blood & cancer

authors： Chen EL,Yoo CH,Gutkin PM,Merriott DJ,Avedian RS,Steffner RJ,Spunt SL,Pribnow AK,Million L,Donaldson SS,Hiniker SM

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:A total of 201 pediatric cases of acute lymphoblastic leukemia were treated with the ALL-96 protocol by the Kyushu-Yamaguchi Children's Cancer Study Group. PROCEDURE:Risk stratification was based on white cell counts, immunophenotype, the presence of central nervous system disease at diagnosis, organomegaly...

journal_title：Pediatric blood & cancer

authors： Nagatoshi Y,Matsuzaki A,Suminoe A,Inada H,Ueda K,Kawakami K,Yanai F,Nakayama H,Moritake H,Itonaga N,Hotta N,Fujita K,Hidaka Y,Yamanaka T,Kawano Y,Okamura J

更新日期：2010-08-01 00:00:00

abstract：BACKGROUND:The Wnt/β-catenin pathway plays a central role in the pathogenesis of most hepatoblastomas (HBs), that is, up to 60-80% carry activating CTNNB1 mutations. HBs can however also be the first manifestation of familial adenomatous polyposis (FAP). As this is a severe disease, it is important for the patient and ...

journal_title：Pediatric blood & cancer

authors： Dubbink HJ,Hollink IHIM,Avenca Valente C,Wang W,Liu P,Doukas M,van Noesel MM,Dinjens WNM,Wagner A,Smits R

更新日期：2018-06-01 00:00:00

abstract：:Adherence is a critical consideration in ongoing efforts to improve outcomes among adolescents and young adults (AYAs) with cancer. In this narrative review, we embed existing conceptualizations of adherence within a developmental context to provide a novel vantage point from which to examine this important issue. App...

journal_title：Pediatric blood & cancer

authors： Vandermorris A,Sampson L,Korenblum C

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Histology after intensive induction chemotherapy is expected to become a beacon indicating when and how extensively radical surgery and lymph node dissection should be performed in advanced neuroblastoma. A thorough histologic review of surgical specimens was undertaken. PROCEDURE:All specimens from 34 pati...

journal_title：Pediatric blood & cancer

authors： Tsuchida Y,Miyauchi J,Kuroiwa M,Suzuki N,Sakamoto J,Suzuki M,Shitara T

更新日期：2005-10-15 00:00:00

abstract：:Congenital amegakaryocytic thrombocytopenia (CAMT) is characterised by neonatal thrombocytopenia, with reduced or absent bone marrow megakaryocytes, leading eventually to pancytopenia. The mean age for progression to bone marrow failure is four years, with the earliest reported being six months. We describe a CAMT pat...

journal_title：Pediatric blood & cancer

authors： Stoddart MT,Connor P,Germeshausen M,Ballmaier M,Steward CG

更新日期：2013-09-01 00:00:00

abstract：:Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently...

journal_title：Pediatric blood & cancer

authors： Coccia P,Mastrangelo S,Ruggiero A,Scalzone M,Rosolen A,Maurizi P,Riccardi R

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Long-term adverse effects of Imatinib in children with chronic myeloid leukemia (CML) are uncertain. The aim was to study the effect of imatinib on growth in children with CML. PROCEDURE:Children ≤13 years of age at diagnosis were enrolled retrospectively, from 2004 to 2011, from a single center in India. P...

journal_title：Pediatric blood & cancer

authors： Bansal D,Shava U,Varma N,Trehan A,Marwaha RK

更新日期：2012-09-01 00:00:00

abstract：:Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β-thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non-progressive increases in serum creatinine, how...

journal_title：Pediatric blood & cancer

authors： Rheault MN,Bechtel H,Neglia JP,Kashtan CE

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Epoetin alfa (EPO, PROCRIT) pharmacokinetics and pharmacodynamics were evaluated in children with malignant solid tumors receiving chemotherapy. PROCEDURE:Children initially received IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks. Dose was increased to 900 IU/kg (max dose 60,000 I...

journal_title：Pediatric blood & cancer

authors： Freeman BB 3rd,Hinds P,Iacono LC,Razzouk BI,Burghen E,Stewart CF

更新日期：2006-10-15 00:00:00